Davita Inc vs Materials Select Sector SPDR Fund — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Materials Select Sector SPDR Fund trades at $49.45 (market cap $7.73B). The key difference: Davita Inc is the larger of the two by market cap, and Materials Select Sector SPDR Fund is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| DVA | XLB | |
|---|---|---|
Market Cap | $11.29B | $7.73B |
Volume | 582,204 | 13,681,146 |
Sector | Health | — |
52-Week High | $240.96 | $53.67 |
52-Week Low | $103.87 | $42.23 |
Typical Hold Time | 113 Days | 70 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
XLB, the Materials Select Sector SPDR ETF, trades at $48.98, down 1.51% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX signaling strong selling pressure. The ETF's portfolio is heavily concentrated in chemicals (49% of assets), and recent news highlights sector volatility amid broader market challenges outside of tech. A dividend of $0.23 is scheduled for September 2026, but financial ratios are currently unavailable.
The outlook for XLB is cautious due to technical weakness and sector cyclicality, though long-term infrastructure and AI-related demand offer potential upside. Risks include economic sensitivity and high concentration, while investor sentiment remains mixed with some analysts seeing value in materials as an AI-resistant play.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →